Silver Book Fact

Antibiotic resistance of Klebsiella pneumoniae on the rise

Resistance of Klebsiella pneumoniae to antibiotics has dramatically increased- from 5.3% to 11.6% for third generation cephalosporins (between 1999 and 2010), and from <0.1% to 4.5% for carbapenams (between 2002 and 2010).

Braykov, Nikolay P., Michael R. Eber, Eili Y. Klein, Daniel J. Morgan, and Ramanan Laxminarayan. Trends in Resistance to Carbapenems and Third-Generation Cephalasporins Among Clinical Isolates of Klebsiella Pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol. 2013; 34(3): 259-68. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/div-classtitletrends-in-resistance-to-carbapenems-and-third-generation-cephalosporins-among-clinical-isolates-of-span-classitalicklebsiella-pneumoniaespan-in-the-united-states-19992010div/92079FCA7AE739268B12B1EA67759598

Reference

Title
Trends in Resistance to Carbapenems and Third-Generation Cephalasporins Among Clinical Isolates of Klebsiella Pneumoniae in the United States, 1999-2010
Publication
Infect Control Hosp Epidemiol
Publication Date
2013
Authors
Braykov, Nikolay P., Michael R. Eber, Eili Y. Klein, Daniel J. Morgan, and Ramanan Laxminarayan
Volume & Issue
Volume 34, Issue 3
Pages
259-68
URL
Read Full Resource

Categories

  • Cost of Disease
  • Prevalence & Incidence

Related Facts

  • Most common principal diagnoses for hospitalized patients with HAIs
    The most common principal diagnoses for hospitalized patients with HAIs are: Septicemia 11.8% Adult respiratory failure 5.9% Complications from surgical or medical care 4.1%  
  • Drug-resistant MRSA expensive to treat
    As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.  
  • Hospital-acquired pneumonia leading cause of HAI
    Hospital-acquired pneumonia (HAP) is the 2nd most frequent cause of hospital-acquired infection, numbering around 300,000 cases each year.  
  • Drug resistant infections cost $16.6 – $26 billion to US healthcare system annually
    Drug-resistant infections cost the U.S. healthcare system between $16.6 and $26 billion in extra costs each year.  
  • Risk of HAIs from hospitalization increases with age
    Hospitalized elderly patients are 2 – 5 times more likely to develop a healthcare-associated infection than younger patients.